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Summary
Background Until now, only imatinib and sunitinib have proven clinical beneﬁ t in patients with gastrointestinal 
stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in 
fatal disease progression. We aimed to assess eﬃ  cacy and safety of regorafenib in patients with metastatic or 
unresectable GIST progressing after failure of at least imatinib and sunitinib.
Methods We did this phase 3 trial at 57 hospitals in 17 countries. Patients with histologically conﬁ rmed, metastatic or 
unresectable GIST, with failure of at least previous imatinib and sunitinib were randomised in a 2:1 ratio (by computer-
generated randomisation list and interactive voice response system; preallocated block design (block size 12); stratiﬁ ed 
by treatment line and geographical region) to receive either oral regorafenib 160 mg daily or placebo, plus best 
supportive care in both groups, for the ﬁ rst 3 weeks of each 4 week cycle. The study sponsor, participants, and 
investigators were masked to treatment assignment. The primary endpoint was progression-free survival (PFS). At 
disease progression, patients assigned placebo could crossover to open-label regorafenib. Analyses were by intention 
to treat. This trial is registered with ClinicalTrials.gov, number NCT01271712.
Results From Jan 4, to Aug 18, 2011, 240 patients were screened and 199 were randomised to receive regorafenib 
(n=133) or matching placebo (n=66). Data cutoﬀ  was Jan 26, 2012. Median PFS per independent blinded central 
review was 4·8 months (IQR 1·4–9·2) for regorafenib and 0·9 months (0·9–1·8) for placebo (hazard ratio [HR] 0·27, 
95% CI 0·19–0·39; p<0·0001). After progression, 56 patients (85%) assigned placebo crossed over to regorafenib. 
Drug-related adverse events were reported in 130 (98%) patients assigned regorafenib and 45 (68%) patients assigned 
placebo. The most common regorafenib-related adverse events of grade 3 or higher were hypertension (31 of 132, 
23%), hand-foot skin reaction (26 of 132, 20%), and diarrhoea (seven of 132, 5%).
Interpretation The results of this study show that oral regorafenib can provide a signiﬁ cant improvement in 
progression-free survival compared with placebo in patients with metastatic GIST after progression on standard 
treatments. As far as we are aware, this is the ﬁ rst clinical trial to show beneﬁ t from a kinase inhibitor in this highly 
refractory population of patients.
Funding Bayer HealthCare Pharmaceuticals.
Introduction
Gastrointestinal stromal tumours (GIST) are the most 
common sarcomas arising in the gastrointestinal tract. 
Worldwide, the annual incidence of GIST is about 
10 cases per million people,1 corresponding to at least 
8000 new cases per year in Europe. Early-stage disease 
can be surgically resected, but more than 40% of cases 
recur and metastasise.2
Cytotoxic chemotherapy, although active in other sub-
types of sarcomas, is ineﬀ ective in metastatic GIST.3,4 
Elucidation of GIST molecular pathophysiology as a 
mutation-driven cancer has facilitated the development 
of targeted kinase-inhibitor therapies that have revolu-
tionised treatment options and clinical outcomes for 
this malignancy.5 About 85% of GIST are caused by 
gain-of-function mutations in the proto-oncogene KIT,6 
which encodes a tyrosine-kinase receptor. These 
mutations result in constitutive ligand-independent 
activation of KIT intracellular signalling.1,7,8 Roughly 8% 
of metastatic GIST are associated with gain-of-function 
mutations in the structurally similar tyrosine-kinase 
receptor gene PDGFRA, encoding the platelet-derived 
growth factor receptor α.6,8,9 Other rare subtypes of 
GIST exist that harbour no mutations in KIT or 
PDGFRA, but are probably driven by other mutations 
in genes such as BRAF, NF1, or those encoding 
subunits of the succinate dehydrogenase (SDH) 
complex.9
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Imatinib mesylate, a selective tyrosine-kinase inhibitor 
of KIT, PDGFRA, and ABL, signiﬁ cantly improves 
clinical outcomes in GIST both as therapy for advanced 
metastatic disease and in the postsurgical adjuvant set-
ting.10–13 However, imatinib therapy is limited by primary 
resistance to the drug in about 15% of patients,5,14–16 and 
more than 80% of patients eventually develop disease 
progression driven by secondary resistance mutations 
located in KIT exons.16–20
The ﬁ rst drug shown deﬁ nitively to provide clinical 
beneﬁ t in GIST after resistance to imatinib was sunitinib 
malate, which has more potent activity against the 
wild-type KIT kinase than the ﬁ rst-line treatment, 
imatinib, and also inhibits several other signalling 
pathways related to tyrosine-kinase receptors, including 
the vascular endothelial growth factor receptors (VEGFR1 
[also known as FLT1], VEGFR2 [KDR], and VEGFR3 
[FLT4]), Fms-like tyrosine kinase-3 (FLT3), and the 
receptor encoded by the proto-oncogene RET.21–25 A 
randomised, placebo-controlled phase 3 trial assessing 
sunitinib in imatinib-resistant patients showed a sig-
niﬁ cant improvement in median time to tumour pro-
gression for sunitinib compared with placebo (all patients 
also received best supportive care).26 However, clinical 
progression and drug resistance to sunitinib sub-
sequently evolve, generally within 1 year of treatment, 
and up to now, no other eﬀ ective therapy has been 
developed for tyrosine-kinase inhibitor-resistant GIST. 
Structural biology studies have explained that the smaller 
sunitinib molecule shows activity in patients who are 
imatinib-resistant because sunitinib is able to avoid steric 
hindrance by gatekeeper mutations that block entrance 
of the larger imatinib molecule to the ATP-binding 
pocket of the KIT protein.27
Regorafenib is a novel, oral multikinase inhibitor that 
blocks the activity of several protein kinases, including 
those involved in the regulation of tumour angiogenesis 
(VEGFR1–3 and TEK), oncogenesis (KIT, RET, RAF1, 
BRAF, and BRAFV600E), and the tumour micro environ-
ment (PDGFR and FGFR).28 In preclinical studies, 
regorafenib showed antitumour activity against human 
GIST and other tumour models.28
After the phase 1 study that deﬁ ned the safety, 
tolerability, and recommended dose of regorafenib in 
unselected patients with solid tumours,29 a phase 2 
multicentre trial was designed and done under inde-
pendent academic sponsorship to assess regorafenib in 
patients with GIST with metastatic disease, after failure 
of at least previous imatinib and sunitinib.30 In that phase 
2 study, regorafenib showed activity against tyrosine-
kinase inhibitor-resistant GIST, including some partial 
responses, a high occurrence of durable stable disease, 
and median progression-free survival (PFS) of 10 months, 
along with the expected incidence of grade 3 toxic eﬀ ects 
of hypertension and hand-foot skin reaction.30 On the 
basis of these data and the preclinical rationale of tar-
geting the pathogenic mutant kinases with a structurally 
distinct small-molecule inhibitor, we did this phase 3 
trial (GIST—regorafenib in progressive disease [GRID]) 
to assess eﬃ  cacy and safety of regorafenib in patients 
with metastatic or unresectable GIST, progressing after 
failure of at least previous imatinib and sunitinib. We 
report the eﬃ  cacy and safety results of this trial; quality-
of-life data were collected and will be reported separately 
and a ﬁ nal analysis of overall survival will be done when 
approximately 136 events have been recorded.
Methods
Study design and participants
We did this randomised, placebo-controlled, multicentre, 
phase 3 trial at 57 hospital sites in 17 countries (Austria, 
Belgium, Canada, China, Finland, France, Germany, 
Israel, Italy, Japan, Netherlands, Poland, Singapore, 
South Korea, Spain, UK, and USA).
Eligibility criteria included histologically conﬁ rmed, 
metastatic or unresectable GIST, with failure of at least 
previous imatinib (deﬁ ned as either disease progression 
or intolerance) and previous sunitinib (deﬁ ned solely as 
progression to decrease heterogeneity, since the def-
inition of intolerance is more variable with this agent 
than with imatinib). Patients could have received other 
systemic therapies, including investigational agents, 
except any VEGFR inhibitors other than sunitinib. 
Additional inclusion criteria included: at least one 
measurable lesion with CT or MRI; resolution of all toxic 
eﬀ ects of previous therapy to grade 1 or lower; adequate 
haematological, hepatic, cardiac, and renal function; and 
an Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0 or 1. The appendix provides add-
itional details of inclusion and exclusion criteria.
The study protocol was approved by the institutional 
review board of each participating institution and com-
plied with the Declaration of Helsinki, existing good 
clinical practice guidelines, and local laws and regula tions. 
An independent data monitoring committee, of three 
oncologists and a statistician, ensured the overall integrity 
of the trial and safety of participants. All participants 
provided written informed consent before enrolment.
Randomisation and masking
Patients were randomly assigned in a 2:1 ratio to 
regorafenib or placebo with a computer-generated ran-
domisation list prepared by the study sponsor (pre-
allocated block design, block size 12). Investigators 
received the randomisation number for each participant 
through an interactive voice response system, which was 
also used to manage study drug supply. Randomisation 
was stratiﬁ ed by treatment line (failure of previous 
imatinib and sunitinib [true third-line] vs failure of 
previous imatinib, sunitinib, and other GIST therapies) 
and geographical region (Asia vs rest of world).
Randomisation was masked so that neither the 
patient, nor the investigator, nor the sponsor knew 
which agent was being administered. To maintain 
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concealment, study medication was labelled with a 
unique drug pack number preprinted on each bottle, 
which was assigned to the patient through the interactive 
voice response system. Unmasking for individual 
patients could occur via the voice response system for 
emergencies; serious adverse events did not necessarily 
precipitate immediate unmasking.
Procedures
Enrolled patients received either oral regorafenib 160 mg 
once daily or matching placebo, for the ﬁ rst 3 weeks of 
each 4 week cycle. All patients also received best sup-
portive care (deﬁ ned as any method to preserve the 
comfort and dignity of the patient, excluding disease-
speciﬁ c antineoplastic therapy, such as tyrosine-kinase 
therapy other than study drug, chemotherapy, radiation 
therapy, or surgical intervention). Masked study drug 
administration was continued until disease progression, 
occurrence of unacceptable toxic eﬀ ects, or withdrawal of 
the patient from the study.
In the event of centrally assessed tumour progression, 
treatment assignment could be unmasked. Patients ori-
ginally assigned to the placebo group were oﬀ ered the 
option to crossover to receive open-label regorafenib, and 
patients originally assigned to the regorafenib group 
could continue to receive open-label regorafenib, both at 
the discretion of the investigator. Throughout both the 
masked and open-label phases of the trial, the dose of 
study drug could be delayed or reduced according to a 
prespeciﬁ ed schedule in the case of unacceptable toxic 
eﬀ ects (appendix).
Tumour assessments were made at baseline, then 
every 4 weeks for the ﬁ rst 3 months, every 6 weeks for the 
next 3 months, and subsequently every 8 weeks until the 
end of study drug administration. Intervening tumour 
assessments could be made more frequently when 
clinically indicated. In addition to central review, an 
investigator assessment was also made at each evalu-
ation. During the open-label period, only investigator 
assessments were made.
We assessed safety and tolerability by analysis of ad-
verse events, physical examinations, vital signs, ECOG 
performance status, and laboratory assessments, on 
days 1 and 15 of each treatment cycle for the ﬁ rst six 
cycles. Cardiac function was assessed with 12-lead 
electrocardiogram at screening, day 1 of the ﬁ rst two 
treatment cycles (and subsequent cycles at the discretion 
of the investigator), and at treatment end. Investigators 
rated severity of adverse events according to the National 
Cancer Institute Common Terminology Criteria for Ad-
verse Events (version 4.0).
The primary endpoint was PFS per modiﬁ ed Response 
Evaluation Criteria In Solid Tumors (RECIST) 1.1, 
assessed by central radiology reviewers who were masked 
to assignment and data from patients. The prospectively 
deﬁ ned RECIST modiﬁ cations, which were unique to 
this study and developed to apply speciﬁ cally to GIST, 
were the following criteria: no lymph nodes were chosen 
as target lesions—enlarged lymph nodes were followed 
up as non-target lesions; no bone lesions were chosen as 
target lesions; and PET was not acceptable for radio-
logical assessment. Additionally a progressively growing 
new tumour nodule within a pre-existing tumour mass 
had to meet the following criteria to be regarded as 
unequivocal evidence of progression according to our 
modiﬁ cation to RECIST 1.1: the lesion was at least 2 cm 
in size and deﬁ nitely a new active GIST lesion (eg, 
enhanced with contrast or other criteria to rule out 
artifact); or the lesion had to be expanding on at least two 
sequential imaging studies. The masked central radiology 
review was done according to a prospectively agreed 
central imaging charter and undertaken by an external 
imaging contract research organisation. Two readers 
reviewed the images. Adjudication by another radiology 
reviewer was used when only one reader assessed a 
progression or when the date of progression was dis-
cordant between the two independent readers.
Secondary endpoints included overall survival, time to 
progression, objective response rate, and disease control 
rate (deﬁ ned as rate of complete response or partial 
response plus stable disease lasting for at least 12 weeks), 
safety, and tolerability. Exploratory endpoints (not 
reported here) were health-related quality of life, pharma-
co kinetics, secondary PFS during open label treatment, 
and biomarker assessment, including tumour genotype 
for mutational status of target oncogene.
Statistical analysis
With 199 patients randomised, assuming a target treat-
ment eﬀ ect of 100% improvement in PFS, a random-
isation ratio of 2:1 (regorafenib to placebo), a one-sided 
alpha of 0·01, and a power of 0·94, 144 events were 
needed for the ﬁ nal PFS analysis. A preplanned interim 
analysis of overall survival was done at the time of the 
ﬁ nal PFS analysis.
We did statistical analyses with SAS (version 9.1 or 
higher). Eﬃ  cacy analyses were by intention to treat. 
Safety analyses included all patients who received at least 
one dose of study drug. We calculated PFS and overall 
survival estimates with the Kaplan-Meier method. We 
derived hazard ratios (HRs) and 95% CIs from a Cox 
proportional hazard model and p values with the 
stratiﬁ ed log-rank test. Overall response rate and disease 
control rate were analysed with the Cochran-Mantel-
Haenszel test. This trial is registered with ClinicalTrials.
gov, number NCT01271712.
Role of the funding source
The study sponsor provided regorafenib and matching 
placebo, and collaborated with the principal investigator 
(GDD) and an international steering committee of aca-
demic investigators on protocol design, data collection and 
interpretation, and preparation of this report. All logistical 
study operations were managed by the sponsor. Data were 
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collected by the sponsor and analysed by the principal 
investigator, steering committee, and sponsor. All authors 
had full access to all data and vouch for the accuracy and 
completeness of the data presentation and analysis. The 
authors had ﬁ nal responsibility to submit for publication.
Results
Between Jan 04, and Aug 18, 2011, 240 patients were 
screened and 199 patients were randomised to receive 
regorafenib (n=133) or placebo (n=66; ﬁ gure 1). One 
patient randomised to the regorafenib group died before 
receiving study treatment. Baseline characteristics and 
previous treatments were much the same between the 
two groups, although by chance a higher proportion of 
patients in the placebo group had received imatinib 
therapy for more than 18 months than in the regorafenib 
group (table 1); 193 patients (97%) had previous disease 
progression while on both imatinib and sunitinib, with 
only six patients (3%) entered with a history of intolerance 
to imatinib. Notably, 86 patients (43%) had received three 
or more previous lines of anticancer therapy for GIST.
Analysis was done when the predetermined criteria of 
144 PFS events was reached: 81 events among the 
133 patients (61%) in the regorafenib group and 63 events 
among the 66 patients (95%) in the placebo group. 
During the double-blind period, 38 patients (29%) in the 
regorafenib group and seven (11%) patients in the 
placebo group discontinued study treatment (appendix). 
The most common reason for termination of study treat-
ment was radiologically conﬁ rmed disease progression.
At the data cutoﬀ  (Jan 26, 2012), 53 (40%) of the 
133 patients in the regorafenib group and three (5%) of 
the 66 patients in the placebo group were still receiving 
double-blind treatment (ﬁ gure 1). A further 41 patients 
(31%) in the regorafenib group continued to receive 
open-label regorafenib after disease progression, and 
24 (18%) of the 41 patients were still receiving regorafenib 
at the time of analysis. In the placebo group, 56 patients 
(85%) crossed over to receive open-label regorafenib after 
progression, and 33 (50%) were still receiving treatment 
at data cutoﬀ  (ﬁ gure 1, appendix). The appendix includes 
a summary of post-study treatments.
240 patients assessed for eligibility
41 excluded
29 did not meet inclusion criteria
5 withdrew consent
4 died
3 adverse events
199 randomised
133 allocated to regorafenib
(double-blind phase)
66 allocated to placebo (double-blind
phase)
1 did not receive regorafenib
132 received regorafenib 66 received placebo
38 discontinued regorafenib
20 radiological progression
1 clinical progression
5 adverse events associated
with progression
3 adverse events not associated
with progression
4 withdrew consent
2 died
2 protocol violation
1 lack of eﬃcacy
94 receiving regorafenib
41 receiving open-label regorafenib
53 undergoing masked treatment
7 discontinued placebo
2 radiological progression
1 clinical progression
4 adverse events associated with
progression
59 receiving study treatment
56 crossed over to open-label
regorafenib
   3 undergoing masked treatment
17 discontinued open-label regorafenib
12 radiological progression
2 adverse events associated with
progression
1 died
2 physician decision
23 discontinued open-label regorafenib
11 radiological progression
2 clinical progression
1 adverse events associated with
progression
3 adverse events not associated
with progression
5 withdrew consent
1 died
77 receiving regorafenib at data cutoﬀ 33 receiving regorafenib at data cutoﬀ
3 receiving placebo at data cutoﬀ
133 included in primary eﬃcacy analysis 66 included in primary eﬃcacy analysis
Figure 1: Trial proﬁ le
Regorafenib 
(N=133)
Placebo 
(N=66)
Median age 60 (51–67) 61 (48–66)
Sex
Men 85 (64%) 42 (64%)
Women 48 (36%) 24 (36%)
Ethnic group
White 90 (68%) 45 (68%)
Black or African American 0 1 (2%)
Asian 34 (26%) 16 (24%)
Not reported or missing 9 (7%) 4 (6%)
ECOG performance status
0 73 (55%) 37 (56%)
1 60 (45%) 29 (44%)
Previous systemic anticancer therapy
2 lines 74 (56%) 39 (59%)
>2 lines 59 (44%) 27 (41%)
Duration of previous imatinib therapy
≤6 months 18 (14%) 4 (6%)
6–18 months 26 (20%) 7 (11%)
>18 months 89 (67%) 55 (83%)
Data are n (%) or median (IQR). ECOG=Eastern Cooperative Oncology Group. 
Table 1: Baseline patient characteristics
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During the double-blind period, patients who were 
assigned to receive regorafenib had a median treatment 
duration of 22·9 weeks (IQR 9·3–28·6), with a mean of 
20·2 weeks (SD 11·6), and patients who were assigned to 
receive placebo had a median treatment duration of 
7·0 weeks (IQR 5·1–11·3), with a mean of 9·1 weeks 
(SD 5·9). The median daily dose during the double-blind 
treatment period was 146·8 mg (IQR 125·1–160·0) for 
regorafenib-treated patients (mean 139·8 mg, SD 22·9) 
and 160 mg (IQR 160·0–160·0) for placebo recipients 
(mean 159·5 mg, SD 3·0). In the regorafenib group, 
patients received 78·0% of the planned dose; in the placebo 
group, patients received 83·8% of the planned dose.
Median PFS was 4·8 months (IQR 1·4–9·2) in the 
regorafenib group and 0·9 months (0·9–1·8) in the 
placebo group, according to blinded central review 
(HR 0·27, 95% CI 0·19–0·39; p<0·0001; ﬁ gure 2A), 
meeting the primary endpoint of the study. PFS at 3 and 
6 months was 60% (95% CI 51–68) and 38% (29–48), 
respectively, for regorafenib, and 11% (3–18) and 0% 
(0–0), respectively, for placebo. Investigator assessment 
showed a median PFS of 7·4 months (IQR 2·7–not 
calculable) in the regorafenib group and 1·7 months 
(0·9–2·7) in the placebo group (HR 0·22, 95% CI 
0·14–0·35; p<0·0001; appendix). Median PFS for the 
56 patients in the placebo group who crossed over to 
open-label regorafenib after progression was 5·0 months 
(IQR 3·1–8·7) per investi gator assessment). We noted no 
signiﬁ cant diﬀ erence in overall survival between the 
regorafenib and placebo groups (29 [22%] events in the 
regorafenib group vs 17 [26%] events in the placebo 
group; HR 0·77, 95% CI 0·42–1·41; p=0·199; ﬁ gure 2B).
We analysed the eﬀ ect of baseline factors on treatment 
eﬀ ect with a Cox proportional hazard model (ﬁ gure 3). 
The beneﬁ ts of regorafenib on centrally assessed PFS 
were identiﬁ ed across all subgroups, except for the small 
subset of patients with duration of imatinib treatment of 
less than 6 months. We identiﬁ ed much the same 
beneﬁ ts of regorafenib in patients whose tumours 
harboured the two most com mon primary KIT mutations 
(exon 11 mutation, n=51, HR 0·212, 95% CI 0·098–0·458; 
exon 9 mutation, n=15, 0·239, 0·065–0·876).
No patients in either group had a complete response, 
whereas six of the 133 patients in the regorafenib group 
and one of the 66 patients in the placebo group had a 
partial response, giving overall response rates of 4·5% 
for regorafenib and 1·5% for placebo. The occurrence of 
stable disease as best response (occurring at any time 
and for any duration) was 71·4% (95 of 133 patients) in 
the regorafenib group and 33·3% (22 of 66 patients) in 
the placebo group. The more clinically meaningful 
disease control rate was 52·6% (70 of 133 patients) for 
regorafenib and 9·1% (six of 66 patients) for placebo 
(95% CI –54·72 to –32·49; p<0·0001).
D uring the double-blind period, all 132 assessable 
patients in the regorafenib group and 61 (92%) of the 
66 patients in the placebo group had adverse events. 
Drug-related adverse events were reported in 130 (98%) 
patients in the regorafenib group and 45 (68%) patients 
in the placebo group (table 2). The most common ad-
verse event of any grade was hand-foot skin reaction, 
which occurred in 74 (56%) patients in the regorafenib 
group and nine (14%) patients in the placebo group. 
Drug-related adverse events of grade 3 or higher were 
reported in 81 (61%) patients assigned regorafenib and 
nine (14%) patients assigned placebo. The most common 
regorafenib-related adverse events of grade 3 or higher 
were hypertension (31 of 132 patients, 23%), hand-foot 
skin reaction (26 of 132, 20%), and diarrhoea (seven of 
132, 5%). Grade 5 adverse events were reported in seven 
(5%) patients in the regorafenib group and three (5%) 
patients in the placebo group. In three patients, the 
Number at risk
Regorafenib
Placebo
82
12
0
0
0·25
0·50
HR 0·27, 95% CI 0·19–0·39; p<0·0001
HR 0·77, 95% CI 0·42–1·41; p=0·199
Su
rv
iv
al
 (%
)
0·75
1·00 Regorafenib
Placebo
2 4
Months since randomisation Months since randomisation
6 8 10 0 2 4 6 8 10 12
72
5
27
0
9
0
126
61
119
57
94
41
39
16
10
3
1
1
A B
Figure 2: Kaplan-Meier survival analysis after treatment with regorafenib or placebo
(A) Progression-free survival, per central review (primary endpoint, ﬁ nal analysis). (B) Overall survival (interim analysis). HR=hazard ratio.
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grade 5 adverse events were deemed by the investigator 
to be drug-related: two (2%) in the regorafenib group 
(cardiac arrest and hepatic failure) and one (2%) in the 
placebo group (fatigue).
Serious adverse events were reported in 38 (29%) of 
132 patients in the regorafenib group and 14 (21%) of 
66 patients in the placebo group during the double-blind 
phase. The most common serious adverse events in 
patients in the regorafenib group were abdominal pain 
(ﬁ ve [4%] patients), fever (three [2%] patients), and 
dehydration (three [2%] patients). In the placebo group 
the most common serious events were fatigue (two [3%] 
patients) and pain (two [3%] patients). Although dose 
modiﬁ cations (appendix) were more frequent in the 
regorafenib group (72% [95 patients] vs 26% [17 patients] 
in the placebo group), the occurrence of adverse events 
that led to permanent discontinuation of treatment was 
much the same between the groups (6% [eight patients] 
in the regorafenib group vs 8% [ﬁ ve patients] in the 
placebo group), showing that adverse events were 
manageable by dose modiﬁ cation without the need to 
discontinue treat ment in most cases.
Discussion
When added to best supportive care, regorafenib sig-
niﬁ cantly improves PFS in a population of patients with 
GIST with progressive disease after failure of all approved 
previous therapies, compared with matching placebo. 
Median PFS with regorafenib was more than ﬁ ve times 
that with placebo, reducing the risk of progression or 
death by 73%. Although the regorafenib group might 
have included patients with more indolent disease, we 
believe that the robust results argue against any such 
confounding eﬀ ect of disease-speciﬁ c variables and 
instead are evidence of regorafenib activity to arrest 
disease progression. 56 (85%) of the 66 patients assigned 
placebo accessed regorafenib after disease progression, 
which could have confounded any potential diﬀ erence in 
overall survival between groups.
GIST is the most common sarcoma subtype.31 Elu-
cidation of GIST molecular pathogenesis has allowed 
rational translation of basic science into clinical therapies 
targeting the root cause of the disease, usually KIT or 
PDGFRA mutations. Inhibition of these driver muta-
tions has improved disease control, leading to increased 
survival of patients with GIST.10,11,26 Despite these ad-
vances, only two tyrosine-kinase inhibitors, imatinib and 
sunitinib, have been shown to be clinically beneﬁ cial to 
patients with GIST, and resistance to these agents even-
tually leads to disease progression and death in most 
patients with advanced GIST. Several other structurally 
distinct inhibitors of KIT and PDGFRA kinases have 
been developed, but, despite promise in control of 
tyrosine-kinase inhibitor-resistant disease in early phase 
trials, until now, none has shown beneﬁ t in prospective 
phase 3 trials (panel).32,33
As with other eﬀ ective kinase inhibitors in tyrosine-
kinase inhibitor-resistant disease, in the present study 
regorafenib did not induce high rates of objective 
tumour response per modiﬁ ed RECIST.26 However, 
disease control rate was higher in patients in the 
regorafenib group than in those in the placebo group, 
suggesting that regorafenib was associated with clinically 
Hazard ratio 
(95% CI)
N
All patients
Anticancer line
Third
Fourth or more
Region
Asia
Rest of world
North America
Not North America
Sex
Men
Women
Age
<65 years
≥65 years
BMI
<25 kg/m2 
25 to <30 kg/m2 
≥30 kg/m2
ECOG score
0
1
Duration of imatinib treatment
<6 months 
≥6 to <18 months 
≥18 months
Mutation biomarkers 
KIT exon 11 mutation
KIT exon 9 mutation
199
113
86
47
152
36
163
127
72
136
63
112
56
22
110
89
22
33
144
51
15
0·27
0·23
0·31
0·30
0·24
0·42
0·22
0·31
0·18
0·30
0·15
0·29
0·24
0·19
0·22
0·30
0·50
0·19
0·24
0·21
0·24
(0·19–0·39)
 
(0·14–0·37) 
(0·18–0·54)
 
(0·15–0·62) 
(0·16–0·37)
(0·19–0·92) 
(0·15–0·34)
 
(0·20–0·48)
(0·09–0·34)
(0·19–0·46)
(0·08–0·30)
(0·18–0·46)
(0·12–0·48) 
(0·06–0·61)
  
(0·14–0·37)
(0·18–0·51)
(0·17–1·73)
(0·07–0·55) 
(0·15–0·36)
(0·10–0·46)  
(0·07–0·88)
 
0 0·5 1·0
Favours regorafenib Favours placebo
1·5 2·0
Figure 3: Progression-free survival by subgroup
BMI=body-mass index. ECOG=Eastern Cooperative Oncology Group.
Regorafenib (N=132*) Placebo (N=66)
Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4
Any event 130 (98%) 77 (58%) 2 (2%) 45 (68%) 5 (8%) 1 (2%)
Hand-foot skin reaction 74 (56%) 26 (20%) 0 9 (14%) 0 0
Hypertension 64 (49%) 30 (23%) 1 (1%) 11 (17%) 2 (3%) 0
Diarrhoea 53 (40%) 7 (5%) 0 3 (5%) 0 0
Fatigue 51 (39%) 3 (2%) 0 18 (27%) 0 0
Oral mucositis 50 (38%) 2 (2%) 0 5 (8%) 1 (2%) 0
Alopecia 31 (24%) 2 (2%) 0 1 (2%) 0 0
Hoarseness 29 (22%) 0 0 3 (5%) 0 0
Anorexia 27 (21%) 0 0 5 (8%) 0 0
Rash, maculopapular 24 (18%) 3 (2%) 0 2 (3%) 0 0
Nausea 21 (16%) 1 (1%) 0 6 (9%) 1 (2%) 0
Constipation 20 (15%) 1 (1%) 0 4 (6%) 0 0
Myalgia 18 (14%) 1 (1%) 0 6 (9%) 0 0
Voice alteration 14 (11%) 0 0 2 (3%) 0 0
Data are n (%). *Excluding one patient who did not receive study treatment.
Table 2: Drug-related adverse events in ≥10% of patients during double-blind treatment period
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meaning ful tumour control in patients with advanced 
GIST after failure of all other approved tyrosine-kinase 
inhibitor therapies.
Eﬃ  cacy analysis in prespeciﬁ ed subgroups showed 
robustness in the beneﬁ t of regorafenib compared with 
placebo in nearly all subgroups. In particular, regorafenib 
had much the same beneﬁ t compared with placebo for 
patients receiving treatment either as third-line therapy 
or as fourth or later line of therapy. This result suggests 
that regorafenib can achieve therapeutic beneﬁ t inde-
pendent of previous treatment regimens. A possible 
explanation is that regorafenib targets several pathways 
contributing to GIST pathogenesis, which might block 
resistance mechanisms.28
The safety proﬁ le of regorafenib in this study was 
much the same as that identiﬁ ed in previous clinical 
trials.29,30 Regorafenib dosing was reasonably well 
tolerated within the predeﬁ ned rules for dose modiﬁ -
cation (dose delays or reductions, with an option to dose 
escalate again on the basis of tolerability; appendix). 
Adverse events leading to permanent treatment dis-
continuation were much the same in the two study 
groups. The most common drug-related adverse events 
in the regorafenib group were hyper tension, hand-foot 
skin reaction, and diarrhoea. Drug-related grade 3 or 
higher hypertension was reported in 31 (23%) of 
132 patients assigned regorafenib and, similarly to other 
therapies targeting the VEGF/VEGFR pathway,26,32 is 
probably related to antiangiogenic eﬀ ects. This adverse 
event could be managed with dose modiﬁ cation and 
appropriate anti hypertensive inter vention. Drug-related 
hand-foot skin reaction is also commonly associated with 
other multi targeted kinase inhibitors.26,32 In GRID, this 
adverse event was generally manageable with dose 
modiﬁ cations and proper care of the aﬀ ected skin area.
This rigorously conducted large-scale international 
collaboration provides robust evidence that regorafenib 
can control progressive GIST after failure of other 
approved kinase inhibitors, and this beneﬁ t is much 
the same across many characteristics of patients, 
including ethnic group, age, performance status, and 
commonly mutated forms of the oncogenic KIT driver 
mutations.  Further work is underway to understand 
more fully the activity of regorafenib among rare 
mutational subtypes of GIST besides these common 
KIT mutant subtypes.
Future studies of regorafenib in GIST will investigate 
further the molecular mechanisms by which the treat-
ment can induce disease control after failure of both 
imatinib and sunitinib. Speciﬁ cally, tumour genotypes 
will be studied as predictive tumour biomarkers in an 
eﬀ ort to correlate molecular subtypes of the disease with 
regorafenib activity. Increased understanding of the key 
pathways involved in successful treatment of GIST 
refractory to both imatinib and sunitinib could provide 
new insight into mechanisms of resistance to molecularly 
targeted therapies.
Panel: Research in context
Systematic review
We searched PubMed articles added since 2010 (last search Aug 15, 2012), the abstracts of 
relevant oncology congresses (American Society of Clinical Oncology [ASCO] annual 
meeting, ASCO Gastrointestinal Cancer Symposium, Connective Tissue Oncology Society 
conference, European Multidisciplinary Cancer Congress, European Society for Medical 
Oncology conference, Molecular Markers in Cancer, Molecular Targets and Cancer 
Therapeutics, Targeted Anticancer Therapies, and the World Congress on Gastrointestinal 
Cancers), and ClinicalTrials.gov. For the scientiﬁ c literature and congress searches, we used 
MeSH and full-text search terms for metastatic or unresectable gastrointestinal stromal 
tumours (GISTs). For PubMed, we used the search terms (“secondary” OR “metastatic” OR 
“unresectable”) AND (“gastrointestinal stromal tumors” OR (“gastrointestinal” AND 
“stromal” AND (“tumor” OR “tumour”)) AND (“2010/01/01” : “2012/12/31”).
For conference searches we used the terms “gastrointestinal stromal tumor” or 
“gastrointestinal stromal tumour”, with results restricted to metastatic or unresectable 
disease (by the conference search engine if possible or manually otherwise). We restricted 
the ClinicalTrials.gov search to agents identiﬁ ed in the scientiﬁ c literature and congress 
searches, including inhibitors of KIT, PDGFRA, HSP90, MTOR, RAF, VEGF, and ABLkinases. 
We placed no date or language restrictions on the search. However, two agents failed to 
show clinical activity in phase 3 trials (nilotinib [Novartis Oncology, Basel, Switzerland] 
and retaspimycin [Inﬁ nity Pharmaceuticals, Cambridge, MA, USA]), and others have not 
entered phase 3 trials in this speciﬁ c indication (eg, everolimus, masitinib, motesanib, 
sorafenib, vatalanib [Novartis Oncology in partnership with Bayer Pharmaceuticals, 
Berlin, Germany], dasatinib [Bristol-Myers Squibb Oncology, New York, NY, USA], 
ganetespib [Synta Pharmaceuticals, Lexington, MA, USA], and pazopanib).
Interpretation
Our work is a translation of the evolving scientiﬁ c understanding of aberrant intracellular 
signalling in GIST. Since 1998, researchers have recognised that most GIST lesions have 
constitutively activated signalling through either the KIT or PDGRFA kinase pathways. The 
existing treatment options for patients with metastatic GIST are limited to only two kinase-
inhibiting drugs, imatinib and sunitinib. Once a patient has disease progressing despite 
therapy with these two agents, no therapeutic options have shown eﬃ  cacy. Our translational 
science has previously suggested that structurally distinct kinase-inhibiting agents with 
novel activities could overcome resistance to imatinib and sunitinib, and thereby oﬀ er 
clinical beneﬁ ts to patients with this life-threatening disease. After promising clinical phase 2 
evidence of antitumour activity of regorafenib in pretreated patients, this international, 
randomised, placebo-controlled phase 3 trial shows that oral regorafenib can indeed provide 
a signiﬁ cant progression-free survival beneﬁ t compared with placebo in patients with 
pretreated, progressive metastatic GIST. The study conﬁ rms that drug-resistant GIST remains 
an oncogene-addicted disease that can be therapeutically targeted by new structural 
inhibitory attacks on the pathogenic mutated kinase. As far as we are aware, this is the ﬁ rst 
clinical trial to show beneﬁ t from a kinase inhibitor after objective resistance to two previous 
kinase-inhibiting therapies in a disease driven by an oncogenic kinase mechanism.
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